Business ❯ Biotechnology

Drug Development

Clinical Trials Clinical Research Artificial Intelligence Regulatory Affairs Autoimmune Diseases Regulatory Compliance AI in Healthcare Antibody Discovery Neuro-immunology Market Performance

Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Design

Investors are backing a push to prove AI-designed drugs in human trials by late 2026.

Evotec Leans Into Biologics as Horizon Overhaul Sets 2026 Reset

Sarepta Reports Early siRNA Data Showing Muscle Delivery as Shares Surge

Variant Bio Launches Agentic AI Genomics Platform as It Secures Boehringer Ingelheim Kidney-Disease Deal

Insilico and Servier Strike Up to $888 Million AI-Oncology Partnership

Chai Discovery Raises $130 Million Series B at $1.3 Billion Valuation

Zealand Pharma Unveils ‘Metabolic Frontier 2030’ With Targets for Five Launches

PsiThera Raises $47.5 Million and Appoints Eric Shaff as CEO to Push Oral TNF Small-Molecule Drugs

Biogen, Dayra Launch $50 Million Pact to Develop Oral Macrocyclic Peptides for Immunology

Abzena, Mabqi Forge Partnership to Link Antibody Discovery With Development and GMP Manufacturing

Roivant’s Brepocitinib Succeeds in 52-Week Dermatomyositis Phase 3 as Companies Target 2026 FDA Filing

NRG Therapeutics Raises £50M to Advance Mitochondrial Neurodegeneration Drug Into the Clinic

Lyten Acquires Northvolt’s European Plants to Scale Lithium-Sulfur Technology

Bristol Myers and Bain Capital Launch $300 Million Immunology Spinout

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research

Sarepta Defies FDA, Keeps Duchenne Gene Therapy on the Market

Biocon Secures CDSCO Approval for Generic Liraglutide

Cargo Therapeutics Ceases Operations Following Clinical and Financial Setbacks

Loyal's Life-Extending Drug for Large Dogs Receives Conditional FDA Approval